Cargando…

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fei, Zhou, Cai-Cun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593374/
https://www.ncbi.nlm.nih.gov/pubmed/26187152
http://dx.doi.org/10.1186/s40880-015-0036-4
_version_ 1782393315077914624
author Zhou, Fei
Zhou, Cai-Cun
author_facet Zhou, Fei
Zhou, Cai-Cun
author_sort Zhou, Fei
collection PubMed
description Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations. This new paradigm has substantially highlighted the treatment of advanced NSCLC, shifting it from standard chemotherapy according to specific histologic subtypes to targeted therapy according to specific oncogenic drivers. The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring activating EGFR mutations has been a representative model of precise medicine in the treatment of NSCLC. As the role of EGFR-TKIs in routine management of patients with advanced NSCLC has been well established, this review provides an overview of alternative targeted therapy in the treatment of NSCLC, including EGFR-TKIs for patients with wild-type EGFR NSCLC, as well as other targeted agents either clinical available or in early- to late-stage development.
format Online
Article
Text
id pubmed-4593374
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45933742015-10-06 Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough Zhou, Fei Zhou, Cai-Cun Chin J Cancer Review Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations. This new paradigm has substantially highlighted the treatment of advanced NSCLC, shifting it from standard chemotherapy according to specific histologic subtypes to targeted therapy according to specific oncogenic drivers. The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring activating EGFR mutations has been a representative model of precise medicine in the treatment of NSCLC. As the role of EGFR-TKIs in routine management of patients with advanced NSCLC has been well established, this review provides an overview of alternative targeted therapy in the treatment of NSCLC, including EGFR-TKIs for patients with wild-type EGFR NSCLC, as well as other targeted agents either clinical available or in early- to late-stage development. BioMed Central 2015-07-18 /pmc/articles/PMC4593374/ /pubmed/26187152 http://dx.doi.org/10.1186/s40880-015-0036-4 Text en © Zhou and Zhou. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhou, Fei
Zhou, Cai-Cun
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title_full Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title_fullStr Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title_full_unstemmed Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title_short Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
title_sort targeted therapies for patients with advanced nsclc harboring wild-type egfr: what’s new and what’s enough
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593374/
https://www.ncbi.nlm.nih.gov/pubmed/26187152
http://dx.doi.org/10.1186/s40880-015-0036-4
work_keys_str_mv AT zhoufei targetedtherapiesforpatientswithadvancednsclcharboringwildtypeegfrwhatsnewandwhatsenough
AT zhoucaicun targetedtherapiesforpatientswithadvancednsclcharboringwildtypeegfrwhatsnewandwhatsenough